Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days

Overview

About this study

Evaluate the safety, tolerability, and efficacy of 28 days of treatment with ALLN-177 for reducing urinary oxalate excretion in patients with secondary hyperoxaluria and kidney stones.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • History of enteric or idiopathic hyperoxaluria or kidney stones
  • Urinary oxalate ≥ 50 mg/24 hours

Exclusion Criteria:

  • Hyperuricosuria
  • Glomerular filtration rate < 45 mL/min/1.73m2
  • Hypercalcemia or hyperthyroidism
  • Autoimmune disorder requiring systemic steroids
  • Acute renal colic, primary hyperoxaluria, pure uric acid and/or cysteine stones, renal tubular acidosis, chronic urinary tract infection, or acute renal failure

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

John Lieske, M.D.

Closed for enrollment

Jacksonville, Fla.

Mayo Clinic principal investigator

William Haley, M.D.

Closed for enrollment

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Mitchell Humphreys, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available
.
CLS-20200427

Mayo Clinic Footer